In ASXL1-mut AML patients, a white blood cell (WBC) count ≥50 × 10<sup>9</sup> /L had significantly poorer 5-year OS and EFS than a WBC count <50 × 10<sup>9</sup> /L (78.0% vs. 44.6%, p = 0.001; 74.8% vs. 44.6%, p = 0.003, respectively), while receiving hematopoietic stem cell transplantation (HSCT) had a higher 5-year OS and EFS (84.5% vs. 48.5%, p = 0.024; 79.5% vs. 49.3%, p = 0.047, respectively). Here, ASXL1 is linked to acute myeloid leukemia.